BRPI0720105A2 - Conjugados de aminoácido não padrões de anfetamina e processos para fabricação e uso dos mesmos - Google Patents

Conjugados de aminoácido não padrões de anfetamina e processos para fabricação e uso dos mesmos

Info

Publication number
BRPI0720105A2
BRPI0720105A2 BRPI0720105-2A2A BRPI0720105A BRPI0720105A2 BR PI0720105 A2 BRPI0720105 A2 BR PI0720105A2 BR PI0720105 A BRPI0720105 A BR PI0720105A BR PI0720105 A2 BRPI0720105 A2 BR PI0720105A2
Authority
BR
Brazil
Prior art keywords
amino acid
same
standard amino
amphtamine
manufacture
Prior art date
Application number
BRPI0720105-2A2A
Other languages
English (en)
Inventor
Travis C Mickle
Original Assignee
Kempharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kempharm Inc filed Critical Kempharm Inc
Publication of BRPI0720105A2 publication Critical patent/BRPI0720105A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
BRPI0720105-2A2A 2006-12-11 2007-12-10 Conjugados de aminoácido não padrões de anfetamina e processos para fabricação e uso dos mesmos BRPI0720105A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86937506P 2006-12-11 2006-12-11
PCT/US2007/087028 WO2008073918A1 (en) 2006-12-11 2007-12-10 Non-standard amino acid conjugates of amphetamine and processes for making and using the same

Publications (1)

Publication Number Publication Date
BRPI0720105A2 true BRPI0720105A2 (pt) 2014-10-07

Family

ID=39512105

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0720105-2A2A BRPI0720105A2 (pt) 2006-12-11 2007-12-10 Conjugados de aminoácido não padrões de anfetamina e processos para fabricação e uso dos mesmos

Country Status (11)

Country Link
US (3) US7776917B2 (pt)
EP (1) EP2101571B1 (pt)
JP (1) JP2010512413A (pt)
CN (1) CN101594778A (pt)
AT (1) ATE509622T1 (pt)
AU (1) AU2007333105A1 (pt)
BR (1) BRPI0720105A2 (pt)
CA (1) CA2672138A1 (pt)
ES (1) ES2364865T3 (pt)
IL (1) IL198930A0 (pt)
WO (1) WO2008073918A1 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060014697A1 (en) * 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
CA2645855C (en) 2006-03-16 2015-02-03 Tris Pharma, Inc. Modified release formulations containing drug-ion exchange resin complexes
ES2364865T3 (es) * 2006-12-11 2011-09-15 Kempharm, Inc. Conjugados de ornitina de la anfetamina y procedimientos de fabricación y de utilización de los mismos.
EP2433655A3 (en) 2007-02-08 2013-05-15 Kempharm, Inc. Homoarginine-prodrugs of amphetamine
DE102007037478B3 (de) 2007-08-08 2008-04-30 Leifheit Ag Wäschetrockenständer
US8614346B2 (en) 2009-06-19 2013-12-24 Cambrex Charles City, Inc. Methods and compositions for preparation of amphetamine conjugates and salts thereof
US20130059914A1 (en) 2010-04-21 2013-03-07 Signature Therapeutics, Inc. Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof
US8779191B2 (en) 2010-12-20 2014-07-15 Cambrex Charles City, Inc. Methods and compositions for preparing lisdexamfetamine and salts thereof
KR101616111B1 (ko) * 2011-07-28 2016-04-27 켐팜 인코포레이티드 메틸페니데이트 프로드러그, 이의 제조 방법 및 사용 방법
JP2014521641A (ja) * 2011-07-29 2014-08-28 ケムファーム， インコーポレイテッド ホモアルギニンプロドラッグおよび／またはアンフェタミンおよび他の興奮剤の抱合体、ならびに同物を作製および使用するためのプロセス
JP6280546B2 (ja) 2012-06-26 2018-02-14 デル マー ファーマシューティカルズ ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
US20140073589A1 (en) * 2012-06-27 2014-03-13 Shire Ag Amphetamine Prodrugs
WO2014058742A1 (en) * 2012-10-09 2014-04-17 Sears Douglas Therapeutic treatment
US10314839B2 (en) 2014-10-20 2019-06-11 Elysium Therapeutics, Inc. Diversion-resistant opioid formulations
US20170056352A1 (en) 2015-08-25 2017-03-02 Rgenix, Inc. PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
AU2016332071B2 (en) 2015-10-01 2019-04-18 Elysium Therapeutics, Inc. Polysubunit opioid prodrugs resistant to overdose and abuse
US10335406B2 (en) 2015-10-01 2019-07-02 Elysium Therapeutics, Inc. Opioid compositions resistant to overdose and abuse
JP2020500220A (ja) 2016-11-15 2020-01-09 クラリア ファーマ ホールディング エービー 医薬製剤
EP3551619B1 (en) 2016-12-11 2024-03-06 Zevra Therapeutics, Inc. Compositions comprising methylphenidate-prodrugs, processes of making and using the same
WO2018160178A1 (en) 2017-03-01 2018-09-07 Rgenix, Inc. Pharmaceutically acceptable salts of b-guanidinopropionic acid with improved properties and uses thereof
AU2018234911B2 (en) 2017-03-17 2024-04-18 Elysium Therapeutics, Inc. Polysubunit opioid prodrugs resistant to overdose and abuse
EP3618877A4 (en) * 2017-04-10 2021-01-13 Shire Pharmaceuticals Inc. METHOD OF TREATMENT USING AN AMPHETAMINE PRODRUG
GB201709141D0 (en) 2017-06-08 2017-07-26 Klaria Pharma Holding Ab Pharmaceutical formulation
US12458592B1 (en) 2017-09-24 2025-11-04 Tris Pharma, Inc. Extended release amphetamine tablets
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
WO2019076675A1 (en) * 2017-10-06 2019-04-25 Instituto De Medicina Molecular TREATMENT OF STATES RELATED TO OBESITY
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
WO2019199731A1 (en) * 2018-04-10 2019-10-17 Shire Pharmaceuticals Inc. Amphetamine prodrug and crystalline froms thereof
GB201808462D0 (en) * 2018-05-23 2018-07-11 Klaria Pharma Holding Ab Pharmaceutical formulation
EP3934635A4 (en) * 2019-03-06 2022-12-07 Ensysce Biosciences, Inc. COMPOSITIONS OF ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF
AU2020258086A1 (en) 2019-04-17 2021-11-11 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
AU2020402994A1 (en) 2019-12-11 2022-06-23 Inspirna, Inc. Methods of treating cancer
TW202309004A (zh) * 2021-08-24 2023-03-01 美商精神醫學公司 藉由使用受控和非受控中間體獲取ｍｄｍａ前驅藥之合成途徑
MX2024003466A (es) 2021-09-29 2024-06-04 Ensysce Biosciences Inc Profarmacos de metadona escindibles por enzimas y metodos de uso de los mismos.

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL99020C (pt) * 1954-06-28
US2881113A (en) 1957-01-29 1959-04-07 Ortho Pharma Corp Therapeutically active compositions containing amphetamines
US2892753A (en) * 1957-02-26 1959-06-30 Boehringer Sohn Ingelheim Central nervous system stimulant
DE1493824A1 (de) 1964-01-27 1969-05-22 Hoffmann La Roche Verfahren zur Herstellung von Aminocarbonsaeureamiden
ES2412409T3 (es) 1997-12-22 2013-07-11 Euro-Celtique S.A. Forma farmacéutica para dosificación oral que comprende una combinación de un agonista opiáceo y un antagonista opiáceo
AU6528400A (en) 1999-08-23 2001-03-19 David M. Ockert Triple drug therapy for the treatment of narcotic and alcohol withdrawal symptoms
AU2001268353A1 (en) 2000-06-09 2001-12-17 The Regents Of The University Of California Method of treating pain using nalbuphine and opioid antagonists
US6417184B1 (en) 2000-09-19 2002-07-09 David M. Ockert Triple drug therapy for the treatment and prevention of acute or chronic pain
US7105486B2 (en) * 2002-02-22 2006-09-12 New River Pharmaceuticals Inc. Abuse-resistant amphetamine compounds
IL163667A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Novel sustained release pharmaceutical compounds to preventabuse of controlled substances
WO2004091499A2 (en) 2003-04-09 2004-10-28 Neose Technologies, Inc. Intracellular formation of peptide conjugates
BRPI0410792B8 (pt) * 2003-05-29 2021-05-25 New River Pharmaceuticals Inc compostos de anfetamina resistentes à dependencia
EP1931357A2 (en) 2005-09-13 2008-06-18 Shire LLC Prodrugs of phentermine
ES2364865T3 (es) 2006-12-11 2011-09-15 Kempharm, Inc. Conjugados de ornitina de la anfetamina y procedimientos de fabricación y de utilización de los mismos.
EP2433655A3 (en) * 2007-02-08 2013-05-15 Kempharm, Inc. Homoarginine-prodrugs of amphetamine

Also Published As

Publication number Publication date
EP2101571A1 (en) 2009-09-23
ES2364865T3 (es) 2011-09-15
EP2101571B1 (en) 2011-05-18
ATE509622T1 (de) 2011-06-15
US20080139653A1 (en) 2008-06-12
US20090234018A1 (en) 2009-09-17
US8101661B2 (en) 2012-01-24
AU2007333105A1 (en) 2008-06-19
CA2672138A1 (en) 2008-06-19
WO2008073918A1 (en) 2008-06-19
IL198930A0 (en) 2010-02-17
CN101594778A (zh) 2009-12-02
EP2101571A4 (en) 2010-01-13
US20100292336A1 (en) 2010-11-18
HK1131518A1 (en) 2010-01-29
US7776917B2 (en) 2010-08-17
JP2010512413A (ja) 2010-04-22

Similar Documents

Publication Publication Date Title
BRPI0720105A2 (pt) Conjugados de aminoácido não padrões de anfetamina e processos para fabricação e uso dos mesmos
WO2008098151A3 (en) Polar hydrophilic prodrugs of amphetamine and other stimulants and processes for making and using the same
BRPI0715579A2 (pt) "composto, composição farmacêutica e uso de um composto"
BRPI0812877A2 (pt) " compostos de piperazina, uso de um composto de piperazina, composição, e, método para combater vegetação indesejada ".
BRPI0816881A2 (pt) Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto.
WO2006082523A3 (en) Pharmaceutical sustained release composition of metformin
NO20092611L (no) Krystallinsk faststoff Rasagilin base
BRPI0720972B8 (pt) compostos análogos de ciclopamina e composições farmacêuticas compreendendo os referidos compostos
BRPI0815709A2 (pt) composro, composição farmacêutica, e, uso de um composto.
CL2007001040A1 (es) Proceso para la preparacion de antagonista de la sustancia p derivado de acil-amino-alquilen-amida.
CY1112653T1 (el) Κρυσταλλικες τροποποιησεις της πυρακλοστροβινης
CL2007002377A1 (es) Compuestos derivados de quinazolina; procedimiento de preparacion; composicion farmaceutica; y su uso como anticancerigeno.
BRPI0607545A2 (pt) composto, uso de um composto de fórmula i ou um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica
TW200621313A (en) Pharmaceutical compositions
EA201000039A1 (ru) Фармацевтическая композиция, включающая солифенацин или его фармацевтически приемлемую соль
WO2007022956A3 (en) Pharmaceutical compositions comprising a ph-dependent drug, a ph modifier and a retarding agent
WO2008068299A3 (en) Hydrobromide salt of an anti-hiv compound
ATE552832T1 (de) Antidepressivum-propharmaka
BRPI0716250A2 (pt) Composto ou sal ou solvato do mesmo, composição farmacêutica, método para o tratamento de doenças, e, uso de um composto
BRPI0619018A2 (pt) composto ou um sal ou solvato farmaceuticamente aceitável do mesmo, uso de um composto, e, composição
NL1031705A1 (nl) Aminozuurderivaten.
WO2006078984A3 (en) Uses of methylphenidate derivatives
CL2007003403A1 (es) Compuestos derivados de pirazol; procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios; y su uso para tratar asma, enfermedad obstructiva cronica, bronquitis, entre otras.
BRPI0816800A2 (pt) Composto, composição farmacêutica, e, uso de um composto.
WO2006078887A3 (en) Methylphenidate derivatives and uses of them

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: KEMPHARM, INC. (US)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2329 DE 25-08-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.